| Page 112 | Kisaco Research

The rise of the 505(b)(2) pathway is changing how branded pharmaceutical and biotech companies approach lifecycle management and litigation. Unlike ANDA generics, 505(b)(2) applicants can enter earlier with differentiated products while relying on branded data, creating a hybrid competitive threat that often falls outside traditional Orange Book assumptions. Join this workshop to hear a discussion around defence strategies from a panel of experts from the generic and innovator industries.

  • How in-house teams can identify and defend against 505(b)(2) challenges.
  • Distinguish ANDA generics from 505(b)(2) applicants and the implications for defence strategy.
  • Identify early warning signs through development activity, regulatory engagement, and competitor monitoring.
  • Analyse how formulation, dosing, and delivery changes are used to avoid listed patents.

Author:

Chris Slavinsky

Chief Legal Officer
Innovo Research

Chris Slavinsky

Chief Legal Officer
Innovo Research

Author:

Christina Brown-Marshall

Principal
Fish & Richardson

Christina Brown-Marshall

Principal
Fish & Richardson

Under Director Squires’ leadership, the PTAB has seen reduced reliance on discretionary denials and a recalibrated role for inter partes review. This session brings together former PTAB faculty and experienced PTAB litigators to examine how institution standards are being applied in practice, why certain challenges are proving less viable than before, and when alternatives such as ex parte re-examination may offer a more effective path.

  • Why challengers are re-assessing IPR risk and turning to ex parte re-examination, including trade-offs around timing, estoppel, and examiner workload.
  • How patent owners are using PTAB uncertainty to influence parallel litigation and settlement leverage.
  • Practical guidance on selecting and sequencing invalidity tools in the current PTAB environment
  • Consider venues in alternative jurisdictions such as the EPO and UPC.

Author:

Deborah Sterling

Director
Sterne Kessler

Deborah Sterling

Director
Sterne Kessler

Author:

Ryan Daniel

VP, Associate GC
Fresenius Kabi

Ryan Daniel

VP, Associate GC
Fresenius Kabi

Author:

Victoria Reines

Principal Counsel, Global Patent Litigation
Sanofi

Victoria Reines

Principal Counsel, Global Patent Litigation
Sanofi

Author:

Scott E. Kamholz

Former Administrative Patent Judge
USPTO

Scott E. Kamholz

Former Administrative Patent Judge
USPTO

This judges’ panel offers candid insight into how courts approach patent disputes involving complex technologies, including software, electronics, and standards-based products. Drawing on recent decisions and, judges from key US jurisdictions will discuss what most influences outcomes from claim construction and technical tutorials to expert testimony and damages models.

Author:

Klaus Grabinski

Honorable Judge & President of the Court of Appeals
Unified Patent Court (UPC)

Klaus Grabinski

Honorable Judge & President of the Court of Appeals
Unified Patent Court (UPC)

Author:

Christopher J. Burke

Magistrate Judge
U.S. District Court for the District of Delaware

Christopher J. Burke

Magistrate Judge
U.S. District Court for the District of Delaware

Author:

MaryJoan McNamara

Administrative Law Judge
US ITC

MaryJoan McNamara

Administrative Law Judge
US ITC

Author:

Roy S. Payne

Magistrate Judge
United States District Court for the Eastern District of Texas

Roy S. Payne

Magistrate Judge
United States District Court for the Eastern District of Texas

Author:

Mark Baghdassarian

Partner
McDermott Will & Schulte

Mark Baghdassarian

Partner
McDermott Will & Schulte

Hatch-Waxman case outcomes are often decided by early choices that shape risk, cost, and leverage long before trial. This session offers a structured review of how companies are building and defending Hatch-Waxman cases, from the first Paragraph IV notice through to final judgement.

  • Identify strategic decision points from Paragraph IV notice to trial, and where early decisions most influence outcomes.
  • Review recent key Hatch-Waxman cases and examine how their outcomes have influenced litigation strategy.
  • Managing evidence, discovery scope, and expert strategy.
  • Compare US Hatch-Waxman litigation strategy to parallel approaches in Canada and other key jurisdictions, including differences in timing, remedies and leverage.

Author:

Kevin Yurkerwich

Senior IP Counsel, IP Lead RLT
Novartis

Kevin Yurkerwich

Senior IP Counsel, IP Lead RLT
Novartis

Author:

Laura Chubb

Director – Global IP Litigation
Organon

Laura Chubb

Director – Global IP Litigation
Organon

Author:

Megan Chacon

Principal
Fish & Richardson

Megan Chacon

Principal
Fish & Richardson

Author:

John Kirkland

Executive Director, Intellectual Property and Litigation Counsel
Alkermes

John Kirkland

Executive Director, Intellectual Property and Litigation Counsel
Alkermes

Author:

Hon. Mitchell S. Goldberg

Former Chief Judge
United States District Court, Eastern District of Pennsylvania

Hon. Mitchell S. Goldberg

Former Chief Judge
United States District Court, Eastern District of Pennsylvania

This presentation uses litigation and settlement data to examine how patent type, timing, and strategy influence settlement outcomes, retained exclusivity, and overall leverage across pharma patent litigation.

Author:

Charles Haisch

Executive VP Legal & Regulatory Analysis
IPD Analytics

Charles Haisch

Executive VP Legal & Regulatory Analysis
IPD Analytics

Author:

Scott Allen

VP Legal & Regulatory Analysis
IPD Analytics

Scott Allen

VP Legal & Regulatory Analysis
IPD Analytics

Gain firsthand insight into how judges from the PTAB and federal courts in key jurisdictions are approaching pharmaceutical and biotech patent disputes. This session offers a rare opportunity to hear directly from the decision-makers on litigation strategy, evidentiary expectations, and what most influences outcomes in complex patent cases.

Author:

Klaus Grabinski

Honorable Judge & President of the Court of Appeals
Unified Patent Court (UPC)

Klaus Grabinski

Honorable Judge & President of the Court of Appeals
Unified Patent Court (UPC)

Author:

Roy Payne

Honorable Judge, Magistrate Judge
US District Court for the Eastern District of Texas

Roy Payne

Honorable Judge, Magistrate Judge
US District Court for the Eastern District of Texas

Author:

Kent Jordan

Former Honorable Judge
US District Court for the District of Delaware & U.S. Court of Appeals for the Third Circuit

Kent A. Jordan is a Director in the Wilmington, Delaware law firm of Richards, Layton & Finger. Previously, since 2006, he served as a United States Circuit Judge for the Third Circuit. Before that, he was a United States District Judge for the District of Delaware from 2002 to 2006. Judge Jordan received a B.A. in Economics in 1981 from Brigham Young University and a J.D. in 1984 from Georgetown University. He was an Assistant United States Attorney and head of the Civil Division in the U.S. Attorney’s Office for the District of Delaware. Later, he served as an officer and as a member of the boards of directors of privately held businesses and was a partner in a law firm. He is an Adjunct Professor of Law at the University of Pennsylvania and Vanderbilt University and has served as President of the Board of Trustees of the American Inns of Court Foundation, as well as on the boards of other non-profit organizations.

Kent Jordan

Former Honorable Judge
US District Court for the District of Delaware & U.S. Court of Appeals for the Third Circuit

Kent A. Jordan is a Director in the Wilmington, Delaware law firm of Richards, Layton & Finger. Previously, since 2006, he served as a United States Circuit Judge for the Third Circuit. Before that, he was a United States District Judge for the District of Delaware from 2002 to 2006. Judge Jordan received a B.A. in Economics in 1981 from Brigham Young University and a J.D. in 1984 from Georgetown University. He was an Assistant United States Attorney and head of the Civil Division in the U.S. Attorney’s Office for the District of Delaware. Later, he served as an officer and as a member of the boards of directors of privately held businesses and was a partner in a law firm. He is an Adjunct Professor of Law at the University of Pennsylvania and Vanderbilt University and has served as President of the Board of Trustees of the American Inns of Court Foundation, as well as on the boards of other non-profit organizations.

Author:

Christopher J. Burke

Magistrate Judge
U.S. District Court for the District of Delaware

Christopher J. Burke

Magistrate Judge
U.S. District Court for the District of Delaware

Author:

Brian P. Murray

Partner
Neal Gerber Eisenberg

Brian counsels clients across the biotechnology, pharmaceutical, chemical, and engineering industries on complex intellectual property and technology disputes. He represents companies in high-stakes patent litigation involving biotechnology and biosynthesis, pharmaceuticals, plastics, telecommunications, and LED technologies, helping clients align legal strategies with scientific, regulatory, and business objectives.

Drawing on his background in pharmaceutical research and development, Brian represents clients in Hatch-Waxman litigation and has helped guide multiple matters through trial.  He also advises those pharmaceutical clients on pre-suit strategy, product selection, portfolio management, formulation development, labeling considerations, and regulatory matters.

A significant portion of Brian’s practice focuses on biotechnology innovators, particularly those developing bioengineering and fermentation technologies. He has extensive experience litigating patents related to metabolic engineering and microbial strain development and is skilled at translating highly technical concepts into clear, compelling litigation and counseling strategies.

Before attending law school, Brian worked as a formulation development scientist at Caraco Pharmaceutical Laboratories and gained experience in pharmaceutical synthesis at Fabbrica Italiana Sintetici S.p.A., providing him with a practical understanding of the industries he serves.

Brian P. Murray

Partner
Neal Gerber Eisenberg

Brian counsels clients across the biotechnology, pharmaceutical, chemical, and engineering industries on complex intellectual property and technology disputes. He represents companies in high-stakes patent litigation involving biotechnology and biosynthesis, pharmaceuticals, plastics, telecommunications, and LED technologies, helping clients align legal strategies with scientific, regulatory, and business objectives.

Drawing on his background in pharmaceutical research and development, Brian represents clients in Hatch-Waxman litigation and has helped guide multiple matters through trial.  He also advises those pharmaceutical clients on pre-suit strategy, product selection, portfolio management, formulation development, labeling considerations, and regulatory matters.

A significant portion of Brian’s practice focuses on biotechnology innovators, particularly those developing bioengineering and fermentation technologies. He has extensive experience litigating patents related to metabolic engineering and microbial strain development and is skilled at translating highly technical concepts into clear, compelling litigation and counseling strategies.

Before attending law school, Brian worked as a formulation development scientist at Caraco Pharmaceutical Laboratories and gained experience in pharmaceutical synthesis at Fabbrica Italiana Sintetici S.p.A., providing him with a practical understanding of the industries he serves.

In light of recent changes in PTAB practice under new USPTO Director John A. Squires, in-house teams are reassessing disclosure risk, IPR exposure, and long-term enforceability, particularly for manufacturing processes, algorithms, and data-driven know-how. This session focuses on how companies are making these calls in practice, and how patent strategy is directly shaping trade secret risk in later disputes.

  • How PTAB institution trends, discretionary denial, and parallel-proceeding strategy are influencing decisions to rely more heavily on trade secrets.
  • Where patent specifications, prosecution history, and expert positions have later been used to argue that information was disclosed and no longer secret.
  • Managing the risk of over-disclosure in patent filings while preserving meaningful trade secret protection.
  • When companies deliberately shift from patenting to trade secret protection over a product’s lifecycle, and what triggers that shift.

Author:

Erica LoRe

Senior Director, Intellectual Property Counsel
Invivyd

Erica LoRe

Senior Director, Intellectual Property Counsel
Invivyd

Author:

Damon Gupta

Senior Patent Counsel
Genentech

Damon Gupta is a Director, Patent Counsel at Spark Therapeutics, Inc., a leader in gene therapy and member of the Roche Group. With over a decade of experience in intellectual property (IP) law and a background in molecular biology, Damon advises biotechnology and pharmaceutical companies on patent strategy, IP transactions, and risk mitigation. At Spark, Damon leads efforts to protect proprietary assets, including trade secrets, manage IP disputes, and provides IP support to cross-functional teams, including R&D, manufacturing, and corporate transactions. Damon holds a J.D. from Chicago-Kent College of Law, an M.S. from Baylor College of Medicine, and a B.S. from The Ohio State University.

Damon Gupta

Senior Patent Counsel
Genentech

Damon Gupta is a Director, Patent Counsel at Spark Therapeutics, Inc., a leader in gene therapy and member of the Roche Group. With over a decade of experience in intellectual property (IP) law and a background in molecular biology, Damon advises biotechnology and pharmaceutical companies on patent strategy, IP transactions, and risk mitigation. At Spark, Damon leads efforts to protect proprietary assets, including trade secrets, manage IP disputes, and provides IP support to cross-functional teams, including R&D, manufacturing, and corporate transactions. Damon holds a J.D. from Chicago-Kent College of Law, an M.S. from Baylor College of Medicine, and a B.S. from The Ohio State University.

Author:

Shane O’Neill

Legal Director
Riyadh Air

Shane O’Neill trained and qualified as a competition lawyer at Freshfields Bruckhaus Deringer where he advised clients in the aerospace and aviation sectors on merger control and antitrust regulatory matters. Since moving in-house he has advised on a broad range of matters including IT outsourcing, IP licensing, data protection, IPO, cybersecurity, commercial negotiations with aerospace OEMS, corporate transactions, and IP strategy. 

Currently, he is Assistant General Counsel at Norsk Titanium, a global leader in metal 3D printing which supplies components to the aerospace, defence, and industrial sectors. He is responsible for a number of corporate areas including driving the company’s IP strategy, creation of IP awareness, trade secret protection, IP portfolio management, IP risk reduction, IP collaboration and cybersecurity.

Shane O’Neill

Legal Director
Riyadh Air

Shane O’Neill trained and qualified as a competition lawyer at Freshfields Bruckhaus Deringer where he advised clients in the aerospace and aviation sectors on merger control and antitrust regulatory matters. Since moving in-house he has advised on a broad range of matters including IT outsourcing, IP licensing, data protection, IPO, cybersecurity, commercial negotiations with aerospace OEMS, corporate transactions, and IP strategy. 

Currently, he is Assistant General Counsel at Norsk Titanium, a global leader in metal 3D printing which supplies components to the aerospace, defence, and industrial sectors. He is responsible for a number of corporate areas including driving the company’s IP strategy, creation of IP awareness, trade secret protection, IP portfolio management, IP risk reduction, IP collaboration and cybersecurity.

Author:

Prashant Girinath

Shareholder
Greenberg Traurig, LLP

Prashant Girinath

Shareholder
Greenberg Traurig, LLP